Literature DB >> 24561654

Epigenetic modifications in colorectal cancer: molecular insights and therapeutic challenges.

Aristeidis G Vaiopoulos1, Kalliopi Ch Athanasoula1, Athanasios G Papavassiliou2.   

Abstract

Colorectal cancer, a leading cause of mortality worldwide, is a multistep disorder that results from the alteration of genetic and epigenetic mechanisms under contextual influence. Epigenetic aberrations, including DNA methylation, histone modifications, chromatin remodeling and non-coding RNAs, affect every aspect of tumor development from initiation to metastasis. Cancer stem cell promotion is also included in the wide spectrum of epigenetic dysregulations. Elucidation of this complex crosstalk network may offer new insights in the molecular interactions involved in the pathogenesis of colorectal carcinogenesis. In the era of translational medicine new horizons are opened for the pursuit of personalized therapeutic approaches and the development of novel and accurate diagnostic, prognostic and therapy-assessment markers. This review discusses the implications of epigenetic mechanisms in tumor biology and their applications "from bench to bedside".
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; DNA methylation; Epigenetics; Histone modification; Prognosis; Therapy

Mesh:

Substances:

Year:  2014        PMID: 24561654     DOI: 10.1016/j.bbadis.2014.02.006

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  45 in total

1.  miR-422a is an independent prognostic factor and functions as a potential tumor suppressor in colorectal cancer.

Authors:  Gui-Xi Zheng; Ai-Lin Qu; Yong-Mei Yang; Xin Zhang; Shou-Cai Zhang; Chuan-Xin Wang
Journal:  World J Gastroenterol       Date:  2016-06-28       Impact factor: 5.742

2.  Epigenetic Regulation by Sulforaphane: Opportunities for Breast and Prostate Cancer Chemoprevention.

Authors:  Lauren L Atwell; Laura M Beaver; Jackilen Shannon; David E Williams; Roderick H Dashwood; Emily Ho
Journal:  Curr Pharmacol Rep       Date:  2015-04-01

Review 3.  Novel molecules as the emerging trends in cancer treatment: an update.

Authors:  Priyanka Sekar; Raashmi Ravitchandirane; Sofia Khanam; Nethaji Muniraj; Ananda Vayaravel Cassinadane
Journal:  Med Oncol       Date:  2022-01-04       Impact factor: 3.064

4.  MicroRNA-539 inhibits colorectal cancer progression by directly targeting SOX4.

Authors:  Jian Zhao; Jian Xu; Rui Zhang
Journal:  Oncol Lett       Date:  2018-06-04       Impact factor: 2.967

Review 5.  Interplay between NRF1, E2F4 and MYC transcription factors regulating common target genes contributes to cancer development and progression.

Authors:  Kaumudi Bhawe; Deodutta Roy
Journal:  Cell Oncol (Dordr)       Date:  2018-07-25       Impact factor: 6.730

6.  Mechanism of action of the atypical retinoid ST1926 in colorectal cancer: DNA damage and DNA polymerase α.

Authors:  Rana Abdel-Samad; Patrick Aouad; Hala Gali-Muhtasib; Zeinab Sweidan; Raed Hmadi; Humam Kadara; Egildo Luca D'Andrea; Alessandra Fucci; Claudio Pisano; Nadine Darwiche
Journal:  Am J Cancer Res       Date:  2018-01-01       Impact factor: 6.166

Review 7.  Flaxseed Bioactive Compounds and Colorectal Cancer Prevention.

Authors:  Jennifer A A DeLuca; Erika L Garcia-Villatoro; Clinton D Allred
Journal:  Curr Oncol Rep       Date:  2018-06-05       Impact factor: 5.075

8.  C-X-C chemokine receptor type 5 gene polymorphism affects gene expression in CD4+ T cells and is associated with increased risk of colorectal cancer.

Authors:  Junjie Xing; Xu Li; Jinke Sui; Guangwen Cao; Chuangang Fu
Journal:  Tumour Biol       Date:  2014-05-16

Review 9.  Modeling colorectal cancers using multidimensional organoids.

Authors:  Ibrahim M Sayed; Amer Ali Abd El-Hafeez; Priti P Maity; Soumita Das; Pradipta Ghosh
Journal:  Adv Cancer Res       Date:  2021-03-26       Impact factor: 6.242

10.  Epigenetics Involvement in Oxaliplatin-Induced Potassium Channel Transcriptional Downregulation and Hypersensitivity.

Authors:  Vanessa Pereira; Sylvain Lamoine; Mélissa Cuménal; Stéphane Lolignier; Youssef Aissouni; Anne Pizzoccaro; Laetitia Prival; David Balayssac; Alain Eschalier; Emmanuel Bourinet; Jérôme Busserolles
Journal:  Mol Neurobiol       Date:  2021-03-26       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.